The global antidiarrhoeals market was valued at about $0.24 billion in 2018 and is expected to grow to $0.27 billion at a CAGR of 2.7% through 2022.
The antidiarrheal drugs market consists of sale of antidiarrheal drugs and related services. Diarrhea is a disease affecting digestive parts of the body such as stomach, large intestine and rectum, esophagus, liver, gallbladder and pancreas and causes loose, watery bowel movements. Loperamide and bismuth subsalicylate are some examples of antidiarrheal drugs.
Rise in the number of diarrhea cases significantly contributes to the growth of antidiarrheal drugs market. According to UNICEF, as of 2016, diarrhea was the second leading cause of death among children under the age of 5 years that is responsible for killing 760,000 children every year. It was also estimated in 2015 that, diarrhea was the leading cause of deaths of 1.31 million people globally, across all the ages. Increasing number of diarrheal cases increases the demand for antidiarrheal drugs.
Increase in the use of biologics medicines poses to be a restraint to the antidiarrheal market. Biologics are medicines derived from living organisms like human beings, animals or other microorganisms using biotechnology and are composed of proteins, sugar, nucleic acids or a combination of each of these substances. Due to their ability to target inaccessible parts using small-molecule therapies, biologics are being preferred over the traditional chemical drugs. This shift is restricting the antidiarrheal drugs market hampering the growth of the market. For example, to treat Crohn's Disease, antidiarrheal medications were being used previously, but with the advent of biologics, demand for antidiarrheal diseases has subsided.
Major companies in the antidiarrheal drug market are merging with other companies in the market to increase their reach and market share. Companies merge with or acquire other companies to expand their market share, diversify their product portfolio, or acquire new technologies. There were 22 deals worth $1.86 billion in 2014, 34 deals worth $33.56 billion in 2015, and 42 deals worth in excess of $44 billion in 2016 in the generic drugs market. For instance, in 2018, GlaxoSmithKline agreed to acquire Novartis AG's 36.5% stake in consumer healthcare business for $ 13 billion with an aim to expand the market.
The antidiarrheal drug industry is governed with regulatory frameworks by agencies such as US Food and Drug Administration Agency (FDA). FDA's guidelines for antidiarrheal drugs are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 335 which gives guidelines for the over the counter (OTC) human use of the antidiarrheal drugs. The subpart C of the regulation focuses on the labelling aspect of such drugs and mandates a statement of identity, which identifies the product is to be used for diarrhea in order to avoid any improper use of the drug. The FDA also regulates the warnings and directions of use of the drugs which are to be printed on cover of these drugs.
In 2018, Piramal Enterprises, a diversified global business conglomerate acquired Digeplex and associated brands from Shreya Lifesciences for an undisclosed sum. The merger will help Piramal Enterprises to expand its gastro-intestinal product portfolio. Shreya Lifesciences is a pharmaceutical company established in India in 2001.
Major players in the market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals.
- Eli Lilly and Co.
- Bayer AG
- Dong-A Pharmaceutical Co. Ltd
- Meda Pharmaceuticals
- Apricus Biosciences
- S.K. Chemicals Co
- Teva Pharmaceutical Industries Ltd
- Produtos Quimicos Farmaceuticos Ltd.
- Johnson & Johnson Services
- Bonro Medical
- Post-T-Vac Medical
- Augusta Medical Systems LLC (Augusta Medical)
- Zephyr Surgical Implants (ZSI)
- Futura Medical
- Endo International plc
- Coloplast A/S
- Boston Scientific Corp
- Seelos Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/d5d40v